Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.40 |
| ▸ | PDE1A | P54750 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580646 | 0.83 | CTSD (0.42) | PDE1BPDE1CPDE1ACA2FYN | |
| SCHEMBL4581296 | 0.71 | TBK1 (0.42) | CHEK1FYNNSD2PDE5AALDH1A1 | |
| SCHEMBL5545737 | 0.70 | CHEK1 (0.42) | CHEK1PDE1BPDE1CPDE1A | |
| SCHEMBL7387274 | 0.70 | APEX1 (0.43) | PDE5AALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL7387267 | 0.70 | APEX1 (0.43) | PDE5AALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL21297274 | 0.65 | PDE4D (0.43) | FYNNSD2GAKALDH1A1LMNA | |
| SCHEMBL1394739 | 0.65 | MAPK1 (0.40) | CHEK1NSD2MAPK1 | |
| SCHEMBL7149759 | 0.64 | PDE4D (0.54) | CHEK1 | |
| SCHEMBL4582130 | 0.63 | TUBB4A (0.42) | FYNALDH1A1LMNACSF1R | |
| SCHEMBL29849308 | 0.62 | PDE1B (0.45) | PDE1BPDE1CPDE1ANSD2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | CHEK1 1791/4885PDE1B 4365/4885PDE1C 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.